We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-6.57%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$992B
AUM Growth
-$120B
Cap. Flow
-$16.9B
Cap. Flow %
-1.7%
Top 10 Hldgs %
27.94%
Holding
3,085
New
108
Increased
1,637
Reduced
1,059
Closed
107

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$4.45B
2
JPM icon
JPMorgan Chase
JPM
+$2.22B
3
TEAM icon
Atlassian
TEAM
+$2.08B
4
NVDA icon
NVIDIA
NVDA
+$1.81B
5
AAPL icon
Apple
AAPL
+$1.67B

Sector Composition

Rank Sector Weight
1 Technology 26.79%
2 Healthcare 17.19%
3 Consumer Discretionary 15.16%
4 Financials 10.74%
5 Communication Services 10.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
REI icon
2876
Ring Energy
REI
$354M
$73K ﹤0.01%
19,100
PLSE icon
2877
Pulse Biosciences
PLSE
$3.09B
$71K ﹤0.01%
14,645
+2,000
+16% +$16.4K
SPPI
2878
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$71K ﹤0.01%
55,026
+6,375
+13% +$5.87K
PSFE icon
2879
Paysafe
PSFE
$352M
$70K ﹤0.01%
1,716
-681
-28% -$28.1K
ATHX
2880
DELISTED
Athersys, Inc. Common Stock
ATHX
$70K ﹤0.01%
4,596
+1,840
+67% +$38.5K
POL
2881
DELISTED
Polished.com Inc.
POL
$69K ﹤0.01%
718
+428
+148% +$42.1K
IQ icon
2882
iQIYI
IQ
$1.28B
$68K ﹤0.01%
14,900
XWEL icon
2883
XWELL
XWEL
$8.7M
$68K ﹤0.01%
3,005
LFMD icon
2884
LifeMD
LFMD
$159M
$67K ﹤0.01%
18,900
AXDX
2885
DELISTED
Accelerate Diagnostics
AXDX
$64K ﹤0.01%
4,455
+2,620
+143% +$74.6K
AWH
2886
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$64K ﹤0.01%
4,088
+153
+4% +$2.65K
CVM icon
2887
CEL-SCI Corp
CVM
$25.9M
$63K ﹤0.01%
+533
New +$86.8K
SRT
2888
DELISTED
Startek Inc.
SRT
$63K ﹤0.01%
14,317
+400
+3% +$1.89K
TIG
2889
DELISTED
Trean Insurance Group, Inc. Common Stock
TIG
$63K ﹤0.01%
+13,348
New +$90K
ZOM
2890
DELISTED
Zomedica Corp.
ZOM
$63K ﹤0.01%
188,000
+71,900
+62% +$23.5K
IMDX
2891
Insight Molecular Diagnostics
IMDX
$147M
$62K ﹤0.01%
2,079
+725
+54% +$23.2K
LHDX
2892
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$62K ﹤0.01%
17,400
HLX icon
2893
Helix Energy Solutions
HLX
$1.49B
$61K ﹤0.01%
+12,706
New +$52.1K
XERS icon
2894
Xeris Biopharma Holdings
XERS
$1.55B
$61K ﹤0.01%
24,000
+11,300
+89% +$27.6K
OESX icon
2895
Orion Energy Systems
OESX
$84.2M
$60K ﹤0.01%
2,130
WVE icon
2896
Wave Life Sciences
WVE
$1.03B
$60K ﹤0.01%
29,982
+12,800
+74% +$31.4K
EGIO
2897
DELISTED
Edgio, Inc. Common Stock
EGIO
$59K ﹤0.01%
+281
New +$46.8K
BFX
2898
DELISTED
BowFlex Inc.
BFX
$57K ﹤0.01%
+13,716
New +$68.2K
ATOS icon
2899
Atossa Therapeutics
ATOS
$23.5M
$56K ﹤0.01%
2,976
+1,320
+80% +$26.8K
MLSS icon
2900
Milestone Scientific
MLSS
$46.8M
$56K ﹤0.01%
36,700

Similar funds

T. Rowe Price Associates's Q1 2022 Portfolio in Review

As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
  • T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
  • T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
  • T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
  • T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
  • T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.